February 26, 2022 : Issue #1189

TOP STORIES — Diabetes News and Research

Predicting the Risk of CVD in Diabetes Patients

How Physical Activity Can Modify Metabolism and Protect Against T2D

Dietary Heme-Iron Intake Increases the Risk of T2D

Comparison of Patients with Diabetes in Rural and Urban Populations

SGLT2is and Risk Reduction of Atrial Arrhythmias SCD in Patients with CIED

Dapagliflozin is a Potential Treatment Option for Chronic Kidney Disease Patients

When I looked back over the past 10 weeks of articles we have shared with you, I was amazed by the number of times we had information on the SGLT2 inhibitors in one of the editions. It is amazing how this class of drugs has gone from a third line treatment for diabetes to a do-all product for multiple diseases. Two of the most published uses are for CV and renal complications and the reduction in risk in all patients. This week our two interns, Aleksandra Kusic, PharmD Candidate, Florida A&M University, and Elmoataz Elmamou, PharmD Candidate, 2022, South College School of Pharmacy, look at the use of these medications to reduce arrhythmias in patients with pacemakers, and why these drugs can make a difference in patients with kidney disease, even if they don’t have diabetes.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Data analysis suggests the need to create CVD prediction models specifically focused on the risk factors that affect patients with type 2 diabetes. 

A recent study from the University of Eastern Finland suggests that consistent physical activity can significantly modify the body’s metabolism, which will reduce the risk of developing type 2 diabetes.

Data from systematic analysis and dose-response meta-analysis suggests that people who take higher amounts of dietary heme-iron are at higher risk of developing type 2 diabetes.

Where a patient resides can impact their diabetes care and comorbidities.  

Patients with cardiac implantable electronic devices (CIEDs) who received an SGLT2i had a significantly lower incidence of atrial arrhythmia (AA) compared to placebo. 

DAPA-CKD trial results indicate a significant benefit for SGLT2 inhibitor dapagliflozin in reducing chronic kidney disease progression and mortality caused by kidney failure and cardiovascular disease, regardless of diabetes status. 

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:

Betsy Adegborioye, PharmD Candidate 2022, South College School of Pharmacy

Njideka Aginam, PharmD Candidate, South College School of Pharmacy

Grace Behr, PharmD/MBA Candidate, Creighton University

Elmoataz Elmamoun, PharmD Candidate, 2022, South College School of Pharmacy

Janet Falade, PharmD Candidate, South College School of Pharmacy

Aleksandra Kusic, PharmD Candidate, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences

Your Friends in Diabetes Care
Steve and Dave

Diabetes In Control
www.diabetesincontrol.com